Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 567

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 567
---
 determined by the closing market price of the underlying stock on the date of grant. Total stock-based compensation expense included in the condensed statements of operations is as follows:

|                                     |     | Three months ended 
          March 31, |     |      |
|                                     |     |               2025 |     | 2024 |
| Research and development            |     |                $51 |     |   $— |
| Selling, general and administrative |     |              1,297 |     |  981 |
| Total                               |     |             $1,348 |     | $981 |

Note 11: Commitments and Contingencies From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. The Company is not currently a party to any material legal proceedings and is not aware of any claims or actions pending against the Company that the Company believes could have a material adverse effect on the Company’s business, operating results, cash flows or condensed financial statements. In the future, the Company might from time to time become involved in litigation relating to claims arising from its ordinary course of business. The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its development work, commercialization activities, including drug product manufacturing, technical transfers, finished commercial product production and supportive costs. The scope of the services under these agreements can generally be modified at any time, and these agreements can generally be terminated by either party after a period of notice and receipt of written notice. There have been no material contract terminations as of March 31, 2025. Note 12: Retirement Plan The Company maintains a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers all employees who meet minimum age requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company had made discretionary matching contributions of 50% of the employee’s contributions, up to a maximum of $6 per year, and contributed $101 for three months ended March 31, 2024. Since January 1, 2025, the Company has made discretionary matching contributions of 100% of the first 4% of employee’s contribution, with no cap, and contributed $80 for three months ended March 31, 2025.